Precise Epitope Organization with Self‐adjuvant Framework Nucleic Acid for Efficient COVID‐19 Peptide Vaccine Construction
- 17 April 2023
- journal article
- research article
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 62 (21) , e202301147
Abstract
Peptide vaccines have advantages in easy fabrication and high safety, but their effectiveness is hampered by the poor immunogenicity of the epitopes themselves. Herein, we constructed a series of framework nucleic acids (FNAs) with regulated rigidity and size to precisely organize epitopes in order to reveal the influence of epitope spacing and carrier rigidity on the efficiency of peptide vaccines. We found that assembling epitopes on rigid tetrahedral FNAs (tFNAs) with the appropriate size could efficiently enhance their immunogenicity. Further, by integrating epitopes from SARS‐CoV‐2 on preferred tFNAs, we constructed a COVID‐19 peptide vaccine which could induce high titers of IgG against the receptor binding domain (RBD) of SARS‐CoV‐2 spike protein and increase the ratio of memory B and T cells in mice. Considering the good biocompatibility of tFNAs, our research provides a new idea for developing efficient peptide vaccines against viruses and possibly other diseases.Keywords
Funding Information
- National Natural Science Foundation of China (52032008, 22277071)
This publication has 25 references indexed in Scilit:
- Concept and Development of Framework Nucleic AcidsJournal of the American Chemical Society, 2018
- Recent advances in self-assembled peptides: Implications for targeted drug delivery and vaccine engineeringAdvanced Drug Delivery Reviews, 2017
- Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human PrimatesACS Infectious Diseases, 2016
- Peptide-based synthetic vaccinesChemical Science, 2015
- A DNA Nanostructure Platform for Directed Assembly of Synthetic VaccinesNano Letters, 2012
- Protein-based nanocarriers as promising drug and gene delivery systemsJournal of Controlled Release, 2012
- Low-valency, but not monovalent, antigens trigger the B-cell antigen receptor (BCR)International Immunology, 2010
- CpG oligonucleotides as adjuvants for vaccines targeting infectious diseasesAdvanced Drug Delivery Reviews, 2009
- Activating B Cell Signaling with Defined Multivalent LigandsACS Chemical Biology, 2007
- CpG oligodeoxynucleotide-enhanced humoral immune response and production of antibodies to prion protein PrPSc in mice immunized with 139A scrapie-associated fibrilsJournal of Leukocyte Biology, 2007